Gnaphalium Stannum
- Manufacturer
- Uriel Pharmacy Inc.
- Effective date
- 2026-06-16
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 4
- Source
- daily-update
- Hydrated at
- 2026-07-15 00:32:39
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - PURPOSE SECTION
Use: Temporary relief of headache.
INDICATIONS & USAGE SECTION
FOR ORAL USE ONLY
DOSAGE & ADMINISTRATION SECTION
Directions: Take the contents of one ampule under the tongue and hold for 30 seconds, then swallow. Follow inside instructions to open ampule.
WARNINGS SECTION
Warnings:
NOT FOR INJECTION
Do not use if allergic to any ingredient. Consult a physician is symptoms worsen. If pregnant or nursing, consult a physician before use.
Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
KEEP OUT OF REACH OF CHILDREN.
OTC - ACTIVE INGREDIENT SECTION
Active Ingredients: Cerebellum (Bovine cerebellum) 17X, Corpora quad. (Bovine Quadrigeminal plate) 17X, Epiphysis (Bovine pineal body) 17X, Gnaphalium (Edelweiss) 17X, Labyrinthus (Bovine inner ear) 17X, Medulla oblongata (Bovine Myelencephalon) 17X, Nervus stat. (Bovine eighth cranial nerve) 17X, Onyx (Nat. Silicic acid with traces of iron oxide and carbon) 20X, Stannum met. (Metallic tin) 20X
INACTIVE INGREDIENT SECTION
Inactive Ingredients: Water, Salt
OTC - QUESTIONS SECTION
Questions? Call 866.642.2858 Uriel, East Troy, WI 53120
www.urielpharmacy.com
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| BIFENTHRIN | ACTIVE INGREDIENT | 6B66JED0KN | 1 | |
| BOS TAURUS BRAIN | ACTIVE INGREDIENT | A1YEE2DB8Z | 1 | |
| BOS TAURUS CEREBELLUM | ACTIVE INGREDIENT | Q09851U44F | 1 | |
| BOS TAURUS NERVE | ACTIVE INGREDIENT | 28G2U3MQJK | 1 | |
| BOS TAURUS PINEAL GLAND | ACTIVE INGREDIENT | Z7RM5NBH36 | 1 | |
| PSEUDOGNAPHALIUM LUTEOALBUM LEAF | ACTIVE INGREDIENT | BGI20Z6M57 | 1 | |
| SUS SCROFA EAR | ACTIVE INGREDIENT | 7DX2J287CV | 1 | |
| TIN | ACTIVE INGREDIENT | 387GMG9FH5 | 1 | |
| BIFENTHRIN | ACTIVE MOIETY | 6B66JED0KN | 1 | |
| BOS TAURUS BRAIN | ACTIVE MOIETY | A1YEE2DB8Z | 1 | |
| BOS TAURUS CEREBELLUM | ACTIVE MOIETY | Q09851U44F | 1 | |
| BOS TAURUS NERVE | ACTIVE MOIETY | 28G2U3MQJK | 1 | |
| BOS TAURUS PINEAL GLAND | ACTIVE MOIETY | Z7RM5NBH36 | 1 | |
| PSEUDOGNAPHALIUM LUTEOALBUM LEAF | ACTIVE MOIETY | BGI20Z6M57 | 1 | |
| SUS SCROFA EAR | ACTIVE MOIETY | 7DX2J287CV | 1 | |
| TIN | ACTIVE MOIETY | 387GMG9FH5 | 1 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Products#
Every source-derived product name is available through these pages.
- Gnaphalium Stannum
- WATER
- SODIUM CHLORIDE
- BOS TAURUS CEREBELLUM
- BOS TAURUS BRAIN
- BOS TAURUS PINEAL GLAND
- PSEUDOGNAPHALIUM LUTEOALBUM LEAF
- SUS SCROFA EAR
- BOS TAURUS NERVE
- BIFENTHRIN
- TIN
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 48951-5027 | 48951-5027-1 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| WATER | 059QF0KO0R | IACT |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| BOS TAURUS CEREBELLUM | Q09851U44F | ACTIB |
| BOS TAURUS BRAIN | A1YEE2DB8Z | ACTIB |
| BOS TAURUS PINEAL GLAND | Z7RM5NBH36 | ACTIB |
| PSEUDOGNAPHALIUM LUTEOALBUM LEAF | BGI20Z6M57 | ACTIB |
| SUS SCROFA EAR | 7DX2J287CV | ACTIB |
| BOS TAURUS NERVE | 28G2U3MQJK | ACTIB |
| BIFENTHRIN | 6B66JED0KN | ACTIB |
| TIN | 387GMG9FH5 | ACTIB |
Source Document#
Older Hydrated Versions#
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 3 | 2018-05-21 | full-release | 2026-06-01 02:09:53 |
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, ORALLY DISINTEGRATING / ORAL | 10 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | GRANULE, FOR SUSPENSION / ORAL | 162 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / NASAL | 7.4 mg/1ml | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | ELIXIR / ORAL | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SYRUP / ORAL | 40 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET / ORAL | 231 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | ELIXIR / ORAL | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | CAPSULE, EXTENDED RELEASE / ORAL | 41 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / ORAL | 148 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | CAPSULE, EXTENDED RELEASE / ORAL | 41 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, FILM COATED / ORAL | 100 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, EXTENDED RELEASE / ORAL | 335.1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, CHEWABLE / ORAL | 20 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, DELAYED RELEASE / ORAL | 97 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, FILM COATED / ORAL | 100 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | GRANULE, FOR SUSPENSION / ORAL | 162 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / ORAL | 1126 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, EXTENDED RELEASE / ORAL | 335.1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, CHEWABLE / ORAL | 20 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | CAPSULE / ORAL | 6 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / SUBCUTANEOUS | 0.7 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | DROPS / ORAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | CAPSULE / ORAL | 6 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SYRUP / ORAL | 40 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, ORALLY DISINTEGRATING / ORAL | 10 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, COATED / ORAL | 54.7 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / ORAL | 1126 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET / ORAL | 231 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / NASAL | 7.4 mg/1ml | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / SUBCUTANEOUS | 0.7 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / ORAL | 148 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / INTRAVENOUS | 6320 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SUSPENSION / ORAL | 98 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, DELAYED RELEASE / ORAL | 97 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / INTRAMUSCULAR | 17 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SUSPENSION / ORAL | 98 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, COATED / ORAL | 54.7 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / INTRAVENOUS | 6320 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / INTRAMUSCULAR | 17 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | DROPS / ORAL | NA |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Gnaphalium Stannum | GNAPHALIUM STANNUM | Uriel Pharmacy Inc. | 86d7c502-859d-4d47-b81a-c0989395a6a9 | 2026-06-16 | Warnings | 48951-5027-1 48951-5027 48951502701 5465cb3f-97e2-345f-e063-6294a90a117e 86d7c502-859d-4d47-b81a-c0989395a6a9 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
